
Non-Sponsored Content
Mylan biosimilar trastuzumab FDA approved for HER2+ breast or metastatic gastric cancer
By: News Feed | Last updated: 1st December 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
biosimilar, FDA, Genentech, HER2, Herceptin, Mylan, Ogivri, Roche, trastuzumab, trastuzumab-dkst
On 1 December 2017, the FDA approved Ogivri® (trastuzumab-dkst, Mylan) as a biosimilar to Herceptin® (trastuzumab, Genentech) for the treatment of patients with HER2-overexpressing breast or metastatic gastric or gastroesophageal junction adenocarcinoma.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients












































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!